Safety and Tolerability Trial of Microbial Inulinase

Gastrointestinal Health Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Tolerability of Microbial Inulinase

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05744700
• Other study ID #: B03-22-01-T0037
• Secondary ID: BCCT-AB-0009
• Status: Completed
• Phase: N/A
• Start date: April 28, 2023
• Est. completion date: October 6, 2023

Study information

• Verified date: October 2023
• Source: BIO-CAT, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objectives of this clinical trial are to: 1) assess the effect of microbial inulinase on gastrointestinal symptoms in healthy participants compared to a placebo, and 2) to assess the safety and tolerability of microbial inulinase in healthy participants compared to a placebo.

Description:

Dietary FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) can be digestively bothersome for certain fiber-intolerant individuals, as well as those with irritable bowel syndrome (Dionne et al.). Oral supplementation of microbial enzymes is a promising strategy to ameliorate gastrointestinal (GI) symptoms-such as bloating, abdominal discomfort, and gas-that are associated with food intolerances. Oral enzyme supplementation with fungal beta-galactosidase (lactase), fungal alpha-galactosidase, and a mixture of microbial and plant proteases have previously been clinically shown to effectively reduce GI symptoms associated with dairy, legume, and gluten consumption, respectively (Lin et al.; Di Stefano et al.; Ido et al.). While alpha-galactosidase effectively hydrolyzes galactan-type FODMAPs, there remains a need to target fructan-type FODMAPs. Preclinical data using an in vitro static GI digestion model showed that the microbial enzyme inulinase can effectively digest fructan-rich substrates (e.g., inulin from chicory root, garlic, and a high-fructan meal mash) better than control conditions under simulated gastric conditions (Guice et al., submitted).

The present study is a randomized, double-blind, placebo-controlled clinical trial to determine the safety and tolerability of microbial inulinase as a digestive enzyme supplement in healthy adults. This clinical trial will include 60 participants who are healthy adults between the ages of 20 to 60 and who regularly consume at least two meals daily. The study duration will be up to 62 days. This trial consists of one screening visit (Visit 1, Day -30 to -15), a baseline visit (Visit 2, Day 1), and an end-of-study visit (Visit 3, Day 29 ± 3).

To assess the effect of inulinase on GI-related symptoms, participants will fill out the paper Gastrointestinal Symptom Rating Scale (GSRS) on a weekly basis over the course of the study. The GSRS is a validated questionnaire containing 15 questions used to assess symptoms that are commonly associated with GI disorders (Machnicki et al.). All 15 questions are rated using a 7-point Likert scale, where higher ratings represent more discomfort. The GSRS score is determined by the score of five subscales: reflux, diarrhea, abdominal Pain, indigestion, and constipation. The reflux score will be calculated as an average score of questions 2 and

3. The diarrhea score will be calculated as an average score of questions 11,12, and 14. The abdominal pain score will be calculated as an average score of questions 1, 4, and 5. The indigestion score will be calculated as an average score of questions 6, 7, 8, and 9. The constipation score will be calculated as an average score of questions 10, 13, and 15. Each subscale score is the domain score. The average of all 5 domain scores will give the GSRS score. The GSRS score and 5 sub-scale (domain) scores will be used for analysis. The scores in Visit 2 will be treated as baseline, and change from baseline to Week 1, Week 2, Week 3, and Week 4 will be calculated, as well as the proportion of participants showing improved scores.

At screening Visit 1 (up to 30 days and no less than 15 days prior to the baseline visit), participants will arrive at the clinic in a fasting state (≥ 10 hours). After participants provide voluntary informed consent, the following information will be recorded, and procedures carried out:

• Collect demographic data (age, sex, ethnicity and race)

• Review medical/health history

• Review/record dietary and lifestyle habits

• Review/record use of concomitant treatments

• Review inclusion/exclusion criteria

• Take anthropometric measurements [height (screening only), weight) and vital signs [heart rate (HR) and blood pressure (BP)]

• Calculate body mass index (BMI; kg/m^2)

• Perform a brief symptom-based physical exam, if necessary

• Collect blood for hematology, clinical chemistry, lipid profile, and hemoglobin A1c (HbA1c)

• Dispense GSRS questionnaire for in-clinic completion

• Dispense GSRS questionnaire for at-home use

• Dispense study product (placebo only) and study diary

After confirming eligibility, from Day -14 to Day -1 (the day prior to baseline visit on Day 1), all participants will complete a 2-week run-in period where they will orally consume the placebo capsule twice daily with their usual two largest meals of the day (one capsule per meal) with the same two meals each day.

At baseline Visit 2 (Day 1), participants will arrive at the clinic in a fasting state (≥ 10 hours). The following visit procedures will occur:

• Collect and review any unused study product

• Review the study diary to assess compliance, concomitant treatments, medical conditions, and changes in health

• Review inclusion/exclusion criteria

• Review medical/health history

• Review any changes in dietary and lifestyle habits

• Take anthropometric measurements and vital signs (HR and BP)

• Calculate BMI using height collected from screening

• Collect blood for hematology, clinical chemistry, and lipid profiling

• Collect blood for lactate, insulin, uric acid, and high sensitivity C-reactive protein (hsCRP)

• Collect urine for pregnancy test

• Collect the GSRS questionnaire completed during the run-in period

• Dispense GSRS questionnaire for the participant to complete in-clinic

• Dispense GSRS questionnaire for at-home use

• Randomize the participant to inulinase or placebo

• Dose of study product in-clinic

• Adverse Event (AE) monitoring

• Dispense study products and study diary for home use by the participant

At the baseline visit on Day 1, participants will be randomized in a 1:1 ratio to either study product [1,000 units of inulinase activity (INU) per serving] or placebo and then start the 28 ± 3 days of twice daily study product consumption. Study product will be taken in the same manner (1 capsule taken twice daily with their two usual larger meals of the day).

At end-of-study Visit 3 (Day 29 ± 3), participants will arrive at the clinic in a fasting state (≥ 10 hours). The following visit procedures will occur:

• Return any unused study product and packaging of used study product

• Collect and review the study diary to assess compliance

• Review any changes in dietary and lifestyle habits

• Measure vital signs (BP and HR) and weight, and calculate BMI

• Collect urine for pregnancy test

• Collect blood for hematology, clinical chemistry, and lipid profiling

• Collect blood for lactate, insulin, uric acid, and hsCRP

• Collect the GSRS questionnaire and review for completion

• Dispense GSRS questionnaire for the participant to complete in-clinic

• AE monitoring

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: October 6, 2023
• Est. primary completion date: October 6, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Healthy adult participants who are 20 to 60 years of age at screening (inclusive)

2. In good general health (no uncontrolled diseases or conditions) as deemed by the investigator and able to consume the study product

3. Regularly consumes at least 2 meals per day

4. Has a body mass index (BMI) between 18.5 to 29.9 kg/m^2 (inclusive) at Visit 2

5. Completes the run-in period with = 90% product compliance for both consumption of doses and timing of doses as assessed by daily diary

6. Completes the Gastrointestinal Symptom Rating Scale (GSRS) questionnaire during the run-in period

7. Individuals with childbearing potential must agree to practice an acceptable form of birth control for a certain time frame prior to the first dose of study product and throughout the study

8. Has maintained stable use of medication and supplements, and stable dietary and lifestyle habits, for the last 3 months prior to screening and agree to maintain them throughout the study

9. Agree to avoid strenuous exercise 24 hours prior to each visit

10. Willing to limit daily alcohol consumption to no more than 3-4 drinks per day throughout the study

11. Willing to maintain current use of cannabinoids (if applicable) throughout the study

12. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures

Exclusion Criteria:

1. Individuals who are lactating, pregnant, or planning to become pregnant during the study

2. Has a known sensitivity, intolerability, or allergy to any of the study products or their excipients

3. Received a vaccine for COVID-19 (coronavirus disease 2019) in the 2 weeks prior to screening or plans to receive a vaccine for COVID-19 during the study period, currently has COVID-19 or tests positive for COVID-19 within 28 days prior to baseline visit, or currently has any post COVID-19 condition(s) as defined by World Health Organization

4. Recent (within 2 weeks of Visit 1) history of an episode of acute gastrointestinal illness such as nausea, vomiting, or diarrhea

5. Have a history of irritable bowel syndrome, inflammatory bowel disease (including ulcerative colitis and Crohn's disease), functional constipation or diarrhea (defined by the Rome IV diagnostic criteria), celiac disease, malabsorption, gastroparesis, diverticulosis, gastric or duodenal ulcers, pancreatitis, or eating disorder; or have a history of intestinal surgery (excluding appendectomy or herniorrhaphy) or bariatric surgery.

6. Have an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and/or digestion (e.g., history of bowel obstruction)

7. Participated in upper gastrointestinal endoscopy and/or colonoscopy or preparation within 3 months prior to Visit 1

8. Diagnosed with hypercholesterolemia or hypertriglyceridemia [i.e., elevated fasting low-density lipoprotein (LDL) (= 135 mg/dL; = 3.5 mmol/L) or elevated triglycerides (= 150 mg/dL; = 1.7 mmol/L) at screening]

9. Has a history of heart disease/cardiovascular disease, uncontrolled hypertension (= 140 systolic or = 90 diastolic mmHg), kidney disease (dialysis or renal failure), hepatic impairment or disease

10. Is Type I or Type II diabetic or pre-diabetic [i.e., elevated fasting blood glucose levels (= 100 mg/dL; = 5.6 mmol/L) and/or elevated hemoglobin A1c (= 6.0%) at screening]

11. Has a history of liver or gallbladder disease or stomach ulcers

12. Has a positive medical history of unstable thyroid disease, previously diagnosed major affective disorder, psychiatric disorder that required hospitalization in the prior year, immune disorders and/or immunocompromised

13. Diagnosed with cancer (except localized skin cancer without metastases or in situ cervical cancer) within 5 years prior to the screening visit, or any clinically significant disease or disorder which, in the opinion of the investigator, may either put the potential participant at risk because of participation in the study, or influences the results or the potential participant's ability to participate in the study

14. Major surgery in 3 months prior to screening or planned major surgery during the study

15. History of alcohol or substance abuse (including cannabinoids) in the 12 months prior to screening (including having been hospitalized for such in an in-patient or out-patient intervention program)

16. Extreme dietary habits at the discretion of the Qualified Investigator, evidenced by a diet wherein the ratio of individual macronutrients and dietary fiber is markedly different than the typical American diet [e.g., ketogenic diet, Atkins diet, low FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet, vegetarian diet, fruitarian diet, etc.]

17. Use of any treatment listed in Study Protocol (No. B03-22-01-T0037) Section 6.5 (Concomitant Treatments) outside of the permitted time frames and/or conditions.

18. Receipt or use of investigational products in another research study within 28 days prior to baseline (Visit 2) or longer if the previous investigational product is deemed by the investigator to have lasting effects that might influence the eligibility criteria or outcomes of current study

19. Self-report of blood donation totaling between 101 mL to 449 mL of blood within 30 days prior to screening or a blood donation of more than 450 mL within 56 days prior to baseline

20. Self-report of donating plasma (e.g., plasmapheresis) within 14 days prior to screening.

21. Any other active or unstable medical conditions or use of medications/supplements/therapies that, in the opinion of the investigator, may adversely affect the participant's ability to complete the study or its measures or pose a significant risk to the participant

Related Conditions & MeSH terms

• Digestive Health
• Gastrointestinal Health

Intervention

Dietary Supplement:
• Inulinase
Participants will consume one capsule containing 1,000 INU inulinase, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
• Maltodextrin placebo
Participants will consume one capsule containing maltodextrin, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.

Locations

Country	Name	City	State
Canada	Nutrasource site (Apex Trials)	Guelph	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
BIO-CAT, Inc.	Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

Country where clinical trial is conducted

Canada, 

References & Publications (5)

Di Stefano M, Miceli E, Gotti S, Missanelli A, Mazzocchi S, Corazza GR. The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms. Dig Dis Sci. 2007 Jan;52(1):78-83. doi: 10.1007/s10620-006-9296-9. Epub 2006 Dec 7. — View Citation

Dionne J, Ford AC, Yuan Y, Chey WD, Lacy BE, Saito YA, Quigley EMM, Moayyedi P. A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. Am J Gastroenterol. 2018 Sep;113(9):1290-1300. doi: 10.1038/s41395-018-0195-4. Epub 2018 Jul 26. — View Citation

Ido H, Matsubara H, Kuroda M, Takahashi A, Kojima Y, Koikeda S, Sasaki M. Combination of Gluten-Digesting Enzymes Improved Symptoms of Non-Celiac Gluten Sensitivity: A Randomized Single-blind, Placebo-controlled Crossover Study. Clin Transl Gastroenterol. 2018 Sep 19;9(9):181. doi: 10.1038/s41424-018-0052-1. — View Citation

Lin MY, Dipalma JA, Martini MC, Gross CJ, Harlander SK, Savaiano DA. Comparative effects of exogenous lactase (beta-galactosidase) preparations on in vivo lactose digestion. Dig Dis Sci. 1993 Nov;38(11):2022-7. doi: 10.1007/BF01297079. — View Citation

Machnicki G, Pefaur J, Gaite L, Linchenco AM, Raimondi C, Schiavelli R, Otero A, Margolis MK. Gastrointestinal (GI)-Specific patient reported outcomes instruments differentiate between renal transplant patients with or without GI symptoms: results from a South American cohort. Health Qual Life Outcomes. 2008 Jul 21;6:53. doi: 10.1186/1477-7525-6-53. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gastrointestinal Symptom Rating Scale score	Between placebo and inulinase treatments, change from baseline to Day 7, Day 14, Day 21, and Day 28 in Gastrointestinal Symptom Rating Scale scores (overall score and domain scores). All 15 questions are rated using a 7-point Likert scale (1 to 7), where lower ratings represent a better outcome or less discomfort.	4 weeks
Primary	Gastrointestinal Symptom Rating Scale improvement	Between placebo and inulinase treatments, percentage of participants showing improvement from baseline to Day 28 as assessed by reduction of Gastrointestinal Symptom Rating scores (overall score and domain scores). All 15 questions are rated using a 7-point Likert scale (1 to 7), where lower ratings represent a better outcome or less discomfort.	4 weeks
Primary	Abdominal discomfort, bloating, and burping scores	Between placebo and inulinase treatments, change from baseline to Day 7, Day 14, Day 21, and Day 28 on individual Gastrointestinal Symptom Rating Scale questions on abdominal discomfort, bloating, and burping. These 3 questions are rated using a 7-point Likert scale (1 to 7), where lower ratings represent a better outcome or less discomfort.	4 weeks
Primary	Plasma lactate	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting plasma lactate concentration (mmol/L)	4 weeks
Primary	Serum insulin	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum insulin concentration (pmol/L)	4 weeks
Primary	Serum uric acid	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum uric acid concentration (umol/L)	4 weeks
Primary	Serum high-sensitivity C-reactive protein (hsCRP)	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum hsCRP concentration (mg/L)	4 weeks
Primary	Serum total cholesterol	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum total cholesterol concentration (mmol/L)	4 weeks
Primary	Serum low-density lipoprotein (LDL) cholesterol	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum LDL cholesterol concentration (mmol/L)	4 weeks
Primary	Serum high-density lipoprotein (HDL) cholesterol	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum HDL cholesterol concentration (mmol/L)	4 weeks
Primary	Plasma high-density lipoprotein (HDL) cholesterol	Between placebo and inulinase treatments, change from screening to Day 28 in fasting plasma HDL cholesterol concentration (mg/dL)	6 weeks
Primary	Serum triglycerides	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum triglycerides concentration (mmol/L)	4 weeks
Primary	Serum albumin	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum albumin concentration (g/L)	4 weeks
Primary	Serum alkaline phosphatase	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum alkaline phosphatase concentration (U/L)	4 weeks
Primary	Serum alanine transaminase	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum alanine transaminase concentration (U/L)	4 weeks
Primary	Serum aspartate transaminase	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum aspartate transaminase concentration (U/L)	4 weeks
Primary	Serum chloride	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum chloride concentration (mmol/L)	4 weeks
Primary	Serum creatinine	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum creatinine concentration (umol/L)	4 weeks
Primary	Serum globulin	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum globulin concentration (g/L)	4 weeks
Primary	Serum glucose	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum glucose concentration (mmol/L)	4 weeks
Primary	Serum potassium	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum potassium concentration (mmol/L)	4 weeks
Primary	Serum sodium	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum sodium concentration (mmol/L)	4 weeks
Primary	Serum total bilirubin	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum total bilirubin concentration (umol/L)	4 weeks
Primary	Serum total protein	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting serum total protein concentration (g/L)	4 weeks
Primary	Whole blood basophils	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting whole blood basophil count (x 10^9/L)	4 weeks
Primary	Whole blood eosinophils	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting whole blood eosinophil count (x 10^9/L)	4 weeks
Primary	Whole blood hematocrit	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting whole blood hematocrit (as volume percent)	4 weeks
Primary	Whole blood hemoglobin	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting whole blood hemoglobin concentration (g/dL)	4 weeks
Primary	Whole blood lymphocytes	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting whole blood lymphocyte count (x 10^9/L)	4 weeks
Primary	Whole blood mean corpuscular hemoglobin	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting whole blood mean corpuscular hemoglobin (pg)	4 weeks
Primary	Whole blood mean corpuscular hemoglobin concentration	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting whole blood mean corpuscular hemoglobin concentration (g/L)	4 weeks
Primary	Whole blood mean corpuscular volume	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting whole blood mean corpuscular volume (fL)	4 weeks
Primary	Whole blood monocytes	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting whole blood monocyte count (x 10^9/L)	4 weeks
Primary	Whole blood neutrophils	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting whole blood neutrophil count (x 10^9/L)	4 weeks
Primary	Whole blood platelets	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting whole blood platelet count (x 10^9/L)	4 weeks
Primary	Whole blood mean platelet volume	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting whole blood mean platelet volume (fL)	4 weeks
Primary	Whole blood red blood cells	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting whole blood red blood cell count (x 10^9/L)	4 weeks
Primary	Whole blood red blood cell distribution width	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting whole blood red blood cell distribution width	4 weeks
Primary	Whole blood white blood cells	Between placebo and inulinase treatments, change from baseline to Day 28 in fasting whole blood white blood cell count (x 10^9/L)	4 weeks
Primary	Whole blood hemoglobin A1c (HbA1c)	Fasting whole blood HbA1c concentration at Day 1 (%)	Day 1
Primary	Estimated glomerular filtration (eGFR)	Between placebo and inulinase treatments, change from baseline to Day 28 in eGFR (mL/min/1.73m^2)	4 weeks
Primary	Blood pressure	Resting systolic blood pressure over resting diastolic blood pressure (mmHg/mmHg)	4 weeks
Primary	Heart rate	Resting heart rate (beats per minute)	4 weeks
Primary	Body weight	Body weight (kg)	4 weeks
Primary	Body mass index	Body mass index (kg/m^2)	4 weeks
Primary	Incidence of adverse events	Number of participants with adverse events	4 weeks
Primary	Incidence of serious adverse events	Number of participants with serious adverse events	4 weeks